KRAS and non-small cell lung carcinoma: Combined treatment resulted in synergistic growth inhibition in 2 out of 3 KRAS-mut NSCLC cell lines (Additional file 1: Figure S3) but, was frankly antagonistic in two KRAS wild-type cell lines (Additional file 1: Table S1).